Rac2 in integrin macrophage function
Rac2 in integrin macrophage function
批准号:
6595701
负责人:
DONALD DURDEN
金额:
$21.74万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-04-22 至 2007-03-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Preliminary data from our laboratory has established a marked defect in alphavbeta3 and alpha4beta1 integrin directed migration of macrophages of vitronectin in the Rac2-/- mice. The alphavbeta3 and alpha4beta1 integrins mediate important components of inflammation. Macrophages must use the alphav integrins to migrate to sites of inflammation where they modulate inflammation and angiogenesis. Moreover the alphav integrins non-covalently associated with matrix degrading enzymes, MMPs and plasminogen activating systems to digest and remodel the extracellular matrix a necessary component of wound healing, inflammation and angiogenesis. Recent evidence has implicated the alphavbeta3 integrin as an important component of autoimmune arthritis and agents which block alphavbeta3 (function blocking monoclonal antibodies, LM609 and/or RGD peptides) can ameliorate the arthritic state. Both inflammation and angiogenesis are critical components of the pathogenesis of autoimmune arthritis. We propose in Aim 1 to examine the effect of Rac2 on alphavbeta3 and alpha4beta1 integrin signaling and migration in macrophages and non-hematopoietic cells in an effort to examine the specificity of Rac2 signaling in blood cells. We will examine blood specific upstream effectors of integrin signaling as possible components of a Rac2-dependent integrin-induced signaling complex in macrophages. In Aim 2 we will generate a Rac2 deficient collagen-induced arthritis model in DBA/1 mice to evaluate the contribution of Rac2 to autoimmunity mediated through control of inflammation and angiogenesis. These combined studies will potentially identify novel targets for development of anti-inflammatory agents for the treatment of arthritis and other autoimmune diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dual PI3K/BRD4 Inhibitory Chemotype for Maximum Inhibition of MYC and Cancer
-
批准号:9828553
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2017
-
负责人:DONALD DURDEN
-
依托单位:
Role of PTEN and PI-3 kinase in medulloblastomagenesis
-
批准号:9312006
-
项目类别:
-
资助金额:$31.56万
-
财政年份:2017
-
负责人:DONALD DURDEN
-
依托单位:
Role of PTEN and PI-3 Kinase in Medulloblastomagenesis
-
批准号:10681197
-
项目类别:
-
资助金额:$30.93万
-
财政年份:2017
-
负责人:DONALD DURDEN
-
依托单位:
Dual PI3K/BRD4 Inhibitory Chemotype for Maximum Inhibition of MYC and Cancer
-
批准号:10833761
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2017
-
负责人:DONALD DURDEN
-
依托单位:
Role of PTEN and PI-3 Kinase in Medulloblastomagenesis
-
批准号:10231271
-
项目类别:
-
资助金额:$30.93万
-
财政年份:2017
-
负责人:DONALD DURDEN
-
依托单位:
Role of PTEN and PI-3 Kinase in Medulloblastomagenesis
-
批准号:10196616
-
项目类别:
-
资助金额:$30.12万
-
财政年份:2017
-
负责人:DONALD DURDEN
-
依托单位:
Dual PI3K/BRD4 Inhibitory Chemotype for Maximum Inhibition of MYC and Cancer
-
批准号:10165036
-
项目类别:
-
资助金额:$48.71万
-
财政年份:2017
-
负责人:DONALD DURDEN
-
依托单位:
Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors
-
批准号:9255563
-
项目类别:
-
资助金额:$29.97万
-
财政年份:2016
-
负责人:DONALD DURDEN
-
依托单位:
A Phase I study of a dual PI3K/BRD4 inhibitor, SF1126 in the treatment of hepatocellular carcinoma | IDE: 74,551
-
批准号:9167160
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2016
-
负责人:DONALD DURDEN
-
依托单位:
Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors
-
批准号:8834750
-
项目类别:
-
资助金额:$20.9万
-
财政年份:2015
-
负责人:DONALD DURDEN
-
依托单位:
Phase 2 Study of Poly-ICLC in the Treatment of Pediatric Low Grade Gliomas
-
批准号:8764195
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2014
-
负责人:DONALD DURDEN
-
依托单位:
Phase 2 Study of Poly-ICLC in the Treatment of Pediatric Low Grade Gliomas
-
批准号:8921959
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2014
-
负责人:DONALD DURDEN
-
依托单位:
Phase 2 Study of Poly-ICLC in the Treatment of Pediatric Low Grade Gliomas
-
批准号:9125663
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2014
-
负责人:DONALD DURDEN
-
依托单位:
Phase 2 Study of Poly-ICLC in the Treatment of Pediatric Low Grade Gliomas
-
批准号:9326010
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2014
-
负责人:DONALD DURDEN
-
依托单位:
Role of Syk and Rac2 in regulation of HIF1alpha and neovascularization.
-
批准号:8036465
-
项目类别:
-
资助金额:$14.44万
-
财政年份:2009
-
负责人:DONALD DURDEN
-
依托单位:
Role of Syk and Rac2 in regulation of HIF1alpha and neovascularization.
-
批准号:7844911
-
项目类别:
-
资助金额:$23.18万
-
财政年份:2009
-
负责人:DONALD DURDEN
-
依托单位:
Role of Syk and Rac2 in regulation of HIF1alpha and neovascularization.
-
批准号:7361487
-
项目类别:
-
资助金额:$4.93万
-
财政年份:2009
-
负责人:DONALD DURDEN
-
依托单位:
PTEN/AKTp53 signaling axis in tumor induced angiogenesis
-
批准号:6545115
-
项目类别:
-
资助金额:$26.52万
-
财政年份:2002
-
负责人:DONALD DURDEN
-
依托单位:
Vascular targeted pan PI-3 kinase inhibitor prodrug, SF1126 for glioma therapy
-
批准号:7892536
-
项目类别:
-
资助金额:$27.66万
-
财政年份:2002
-
负责人:DONALD DURDEN
-
依托单位:
Vascular targeted pan PI-3 kinase inhibitor prodrug, SF1126 for glioma therapy
-
批准号:8067127
-
项目类别:
-
资助金额:$26.83万
-
财政年份:2002
-
负责人:DONALD DURDEN
-
依托单位:
海外基金